市場調查報告書
商品編碼
1403524
到 2030 年雙能量 X光吸收測量市場預測:按類型、技術、應用、最終用戶和地區進行的全球分析Dual-energy X-ray Absorptiometry Market Forecasts to 2030 - Global Analysis By Type, Technology, Application, End User and by Geography |
根據 Stratistics MRC 的數據,2023 年全球雙能量 X光吸收儀(DEXA)市場規模為 6,1952 萬美元,預測期內複合年成長率為 10.0%,到 2030 年將達到 1,20727 萬美元。達到美元。
使用雙能量 X光檢測法(DEXA) 可以準確、非侵入性地測量骨骼密度(BMD) 和身體組成。 DEXA 透過使用具有兩種不同能量水平的低劑量 X光束來區分骨骼、脂肪和瘦肉組織,提供有關個人骨骼健康和整體身體組成的精確資訊。 DEXA 測試通常用於評估骨質疏鬆症,有助於確定骨折風險和骨礦物質流失。
根據國際骨質疏鬆症基金會的數據,50 歲以上的女性和男性中,約有三分之一和五分之一患有骨質疏鬆症。該組織也估計,美國、歐洲和日本有超過 7,500 萬例與骨質疏鬆症有關。
隨著世界老年人口的增加,與老齡化相關的骨質流失或骨質疏鬆症變得越來越普遍。 DEXA 對於診斷這種虛弱至關重要,因為它是一種重要的診斷工具,可進行快速介入以避免骨折和相關併發症。此外,定期 DEXA 檢測對於高齡化人口的持續健康管理是必要的,並鼓勵儘早採取老年保健措施。
醫療機構可能面臨財務困難,不僅因為 DEXA 設備的初始資本支出,而且還因為持續的維護成本。這些成本是由複雜的技術和確保準確性所需的持續校準所驅動的。此外,這種經濟因素強調了醫療保健規劃中財務考慮的必要性,並可能阻止 DEXA 的廣泛採用,特別是在資源匱乏的環境中。
除了臨床診斷之外,DEXA 還可用於研究目的,是評估藥物如何影響骨骼健康的有用工具。此外,DEXA 能夠追蹤骨骼成分和密度的變化,從而能夠更有效、更有針對性地治療骨質疏鬆症等疾病,為藥物開發提供重要資訊。製藥公司和學術機構之間的合作提供了該領域進一步研究的機會。
新的替代技術和競爭形勢的變化對 DEXA 市場構成威脅。 DEXA 在市場上的主導地位受到定量電腦斷層掃描 (QCT) 和周邊定量電腦斷層掃描 (pQCT) 等競爭診斷方式的威脅。此外,隨著替代技術開拓市場並吸引資本和注意力從傳統 DEXA 系統轉移,市場佔有率佔有率和普及可能會受到影響。
雙能量 X光檢測法(DEXA) 市場受到了 COVID-19 爆發的嚴重影響。由於醫療保健服務中斷、為應對流行病相關挑戰而重新分配資源以及安全問題加劇,DEXA 掃描等常規診斷程序有所減少。此外,由於多種因素的綜合作用,DEXA 技術的採用已暫時停滯,包括患者就診醫療機構的次數減少、非緊急預約的延遲以及醫療保健預算的財務限制。但這場大流行也凸顯了預防性照護的價值,只要衛生系統在疫情後復原期間優先考慮常規篩檢和診斷程序,DEXA 就有可能捲土重來。
軸向 DEXA骨質密度檢測設備預計將佔據雙能量 X光檢測法(DEXA) 的最大市場佔有率。這些設備主要用於評估髖部和脊椎的骨骼密度,這是評估骨折和骨質疏鬆症風險的重要區域。軸向 DEXA 掃描可提供有關骨骼健康的高度準確且全面的資訊,幫助醫生診斷骨質疏鬆症等疾病並評估治療效果。此外,軸向配置是各種醫療機構中臨床醫生的首選,因為它們可以對骨骼的中心區域進行徹底檢查。隨著骨質疏鬆症變得越來越普遍,骨骼健康變得越來越重要,軸向 DEXA骨質密度檢測設備對於疾病管理和預防性護理始終至關重要。
在身體組成分析領域,雙能量X光檢測法(DEXA)市場預計將以最高的複合年成長率成長。人們越來越認知到身體組成對整體健康、健身和疾病預防的影響,從而推動了先進診斷工具市場的發展。除了傳統的骨骼密度測試之外,身體組成分析還可以對去脂體重、脂肪分佈和其他重要因素進行全面分析。此外,科技對於解決全球對肥胖、代謝紊亂和導致肌肉萎縮的疾病的擔憂至關重要。
佔據最大佔有率的北美地區繼續保持在雙能量X光吸收儀(DEXA)市場的主導地位。特別是在美國,醫療保健產業十分成熟且技術先進,在醫學研究、最先進的設備和龐大的基礎設施方面投入了大量資金。此外,高水準的醫療保健支出、強力的法規環境以及對技術創新的持續關注也凸顯了該地區的優勢。因此,以美國為中心的北美地區持續對全球醫療保健產業的發展產生重大影響。
預計亞太地區在預測期內的複合年成長率最高。醫療保健基礎設施投資的增加、高齡化和不斷變化的醫療需求以及醫療意識的提高是促成這一顯著成長的因素。在製藥、醫療技術和醫療保健服務方面領先的國家是中國、印度和日本。此外,該地區對數位健康解決方案的關注、鼓勵的政府舉措等使亞太地區成為醫療保健轉型的領先中心,對該市場的年複合成長率的成長做出了重大貢獻。
According to Stratistics MRC, the Global Dual-energy X-ray Absorptiometry (DEXA) Market is accounted for $619.52 million in 2023 and is expected to reach $1207.27 million by 2030 growing at a CAGR of 10.0% during the forecast period. Bone mineral density (BMD) and body composition can be measured with accuracy and without invasiveness using dual-energy X-ray absorptiometry (DEXA). DEXA provides precise information about an individual's skeletal health and overall body composition by using low-dose X-ray beams at two different energy levels to differentiate between bone, fat, and lean tissue. DEXA scans are frequently used to evaluate osteoporosis and are useful in determining fracture risk and bone mineral loss.
According to the International Osteoporosis Foundation, around one in three women and one in five men over the age of 50 are suffering from osteoporosis. The organization also estimated that over 75 million patients are associated with osteoporosis in the U.S., Europe, and Japan.
Age-related bone loss, or osteoporosis, is becoming more common as the world's senior population grows. DEXA is essential for diagnosing this vulnerability because it is a critical diagnostic tool that enables prompt interventions to avoid fractures and associated complications. Additionally, regular DEXA scans are required for the ongoing health management of the aging population, which encourages an early approach to senior healthcare.
Healthcare facilities may face financial difficulties with the initial capital expenditure for DEXA equipment as well as continuing maintenance costs. The cost of all this is influenced by the complex technology and constant calibration needed to ensure accuracy. Furthermore, this financial factor highlights the need for financial considerations in healthcare planning and may prevent DEXA from being widely adopted, particularly in settings where resources are scarce.
Beyond clinical diagnostics, DEXA can be used in research applications and is a useful tool for evaluating how medications affect bone health. Moreover, its function in tracking alterations in the composition and density of bone offers vital information for medication development, enabling more effective and focused treatments for diseases like osteoporosis. Opportunities for more research in this area are provided by partnerships between pharmaceutical companies and academic institutions.
Emerging alternative technologies and changing competitive landscapes pose threats to the DEXA market. The dominance of DEXA in the market is threatened by competing diagnostic modalities like quantitative computed tomography (QCT) and peripheral quantitative computed tomography (pQCT). Additionally, market share and adoption rates may be impacted if ongoing developments in alternative technologies draw capital and attention away from conventional DEXA systems.
The market for dual-energy X-ray absorptiometry (DEXA) has been greatly impacted by the COVID-19 pandemic. Routine diagnostic procedures, such as DEXA scans, have decreased as a result of disruptions to healthcare services, the reallocation of resources to address pandemic-related challenges, and increased safety concerns. Furthermore, the adoption of DEXA technology has temporarily stalled due to a combination of factors, including fewer patient visits to healthcare facilities, delays in non-urgent medical appointments, and financial constraints on healthcare budgets. But the pandemic has also highlighted the value of preventive healthcare, which may present prospects for DEXA's comeback as long as healthcare systems give regular screenings and diagnostic procedures top priority during the post-pandemic recovery period.
It is projected that axial DEXA bone densitometers will command the largest market share in dual-energy X-ray absorptiometry (DEXA). These instruments are mainly used to assess the bone mineral density in the hip and spine, which are important regions to assess the risk of fractures and osteoporosis. Axial DEXA scans help physicians diagnose diseases like osteoporosis and evaluate the efficacy of treatments by giving them extremely precise and comprehensive information about bone health. Moreover, clinicians in a variety of healthcare settings prefer the axial configuration because it enables a thorough examination of central skeletal sites. As osteoporosis becomes more common and bone health becomes more important, axial DEXA bone densitometers will always be essential for managing diseases and providing preventive care.
The market for dual-energy X-ray absorptiometry (DEXA) is expected to grow at the highest CAGR in the body composition analysis segment. The market for advanced diagnostic tools has been driven by growing awareness of the influence of body composition on overall health, fitness, and disease prevention. Beyond conventional bone density tests, body composition analysis offers a thorough analysis of lean muscle mass, fat distribution, and other important factors. Additionally, in order to address the global concerns surrounding obesity, metabolic disorders, and conditions that cause muscle wasting, technology is essential.
With the largest share, North America has continued to hold a dominant position in the dual-energy X-ray absorptiometry (DEXA) market. Particularly in the United States, the healthcare industry is well-established and technologically sophisticated, with large expenditures made in medical research, state-of-the-art equipment, and a vast infrastructure. Furthermore, the prominence of the region is emphasized by the high level of healthcare spending, the strong regulatory environment, and the ongoing emphasis on innovation. Because of this, North America-led by the United States-continues to have a significant influence on how the global healthcare sector develops.
The Asia-Pacific region is expected to have the highest CAGR over the projected period. Growing investments in healthcare infrastructure, an aging population with evolving healthcare needs, and growing healthcare awareness are all factors contributing to this notable growth. Leading nations in the advancement of pharmaceuticals, medical technology, and healthcare services are China, India, and Japan. Additionally, the region's emphasis on digital health solutions, along with encouraging government initiatives, positions Asia-Pacific as a major hub for the changing healthcare landscape and contributes significantly to the market's rising compound annual growth rate.
Some of the key players in Dual-energy X-ray Absorptiometry (DEXA) market include Osteometer Meditech Inc, Medilink International, GE Healthcare, Shenzhen XRAY Electric Co., Ltd., BeamMed Ltd, Furuno Electric Co., Ltd., Hologic, Inc., Scanflex Healthcare AB, Medonica Co., Ltd, Fonar Corporation and Swissray Medical AG.
In December 2023, GE Healthcare has entered into a distribution agreement with mobile-first clinical surveillance technology provider, AirStrip to expand AirStrip Cardiology and Patient Monitoring solutions in the US. The mobile application from AirStrip enables clinicians to view clinical data on the web and on mobile devices. It connects with cardiac rhythm strips and 12-lead ECGs, allowing clinicians to monitor numerous patients at the same time and can receive STEMI notifications.
In October 2023, MediLink Therapeutics, announced today that it has entered into a strategic research collaboration and worldwide license agreement with BioNTech SE, a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases, on the development of a next-generation antibody-drug conjugate candidate ("ADC"), against Human Epidermal Growth Factor Receptor 3 (HER3).
In September 2023, Hologic Inc. and Bayer today announced an international partnership to deliver contrast-enhanced mammography (CEM) solutions to improve the detection of breast cancer for women in multiple countries across the European, Canadian and Asia Pacific regions. CEM is a highly sensitive and relatively low-cost breast imaging modality that combines digital mammography with the administration of a contrast agent to support breast cancer diagnosis and guide treatment decisions.